Blood Proteins as Signs of Valve Leaflet Thickening After Aortic Valve Replacement
Looks for blood proteins linked to leaflet thickening in people having transcatheter aortic valve replacement.
Key facts
- Who runs it
- Massachusetts General Hospital
- Where
- Boston, Manchester, and Minneapolis, United StatesSee the 3 sites
- Trial code
- Registry title
- The HALT Biomarker Study
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 300 people, planned
- Started
- 22 Jun 2020
- Expected to end
- 22 Jun 2035
- Type of study
- Interventional, 2 groups
- Treatments tested
- Proteomics Analysis
- Record updated
- 10 November 2021
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults over 65 years who are about to have a heart valve replacement through a leg artery (transfemoral TAVR) for a severely narrowed or worn-out aortic valve. Blood tests will look for proteins linked to valve leaflet thickening (HALT).
- Age
- Over 65 years
- Sex
- All sexes
- Disease stage
- Severe narrowing of the person's own aortic valve (severe native AS), or severe wear of an earlier tissue replacement valve (bioprosthetic valve degeneration).
- Earlier treatment
- People must be having transfemoral TAVR with a Medtronic Evolut R, Evolut Pro or Evolut Pro+ valve. People who take blood thinners long term (chronic anticoagulation therapy) cannot join.
Main reasons for not taking part
- Taking blood thinners long term, or unable to take blood thinners by mouth
- Chronic kidney disease with EGFR<30 ml/min
- Bleeding problems, a known clotting disorder, or blood that clots too easily
- Expected to live less than 12 months due to other illness, such as cancer or severe Alzheimer's disease
- Pregnant, breastfeeding, planning pregnancy within the next 12 months, or in another ongoing device or drug study
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Age > 65 years
- Subject with severe native AS or severe bioprosthetic valve degeneration
- Subject undergoing transfemoral TAVR using a Medtronic Evolut R, Evolut Pro or Evolut Pro+ transcatheter heart valve
Who cannot take part
- Chronic anticoagulation therapy
- Contraindication to systemic oral anticoagulation therapy
- The patient is currently participating in another investigational device or drug study that has not reached its primary objective/endpoint
- Bleeding diathesis or known coagulopathy
- Life-expectancy <12 months due to other medical conditions (e.g., malignancy, severe Alzheimer's disease, etc.)
- Chronic kidney disease with EGFR<30 ml/min
- Hypercoagulable state
- Pregnant, lactating, or planning pregnancy within next 12 months
Where in United States
- Massachusetts General HospitalBoston, United StatesContact: Sammy Elmariah, MD (principal investigator)Taking people
- Catholic Medical CenterManchester, United StatesContact: Fahad S Gilani (principal investigator)Taking people
- Minneapolis Heart InstituteMinneapolis, United StatesContact: Santiago Garcia, MD (principal investigator)Not yet recruiting
About the trial
What the trial wants to find out
The purpose of the HALT Biomarkers study are to identify a panel of circulating proteins that discriminates between patients with and without Hypo-Attenuated Leaflet Thickening (HALT) and can be used to supplement the diagnosis of HALT; to characterize changes in circulating proteins after treatment of HALT with systemic anticoagulation; and to identify circulating proteins that predict the occurrence of HALT.
Read full original descriptionShow less
The study population will be adult patients undergoing transfemoral transcatheter aortic valve replacement (TAVR) for severe aortic stenosis (AS) or bioprosthetic valve degeneration. Enrollment will continue until 30 patients with HALT are identified for completion of phase 1. Based on a HALT incidence rate of 10%, we anticipate enrolling 300 patients.
Patients are enrolled prior to undergoing transfemoral TAVR. Blood samples, clinical data and echocardiograms will be collected at the following timepoints: baseline (pre-TAVR, T0), post-TAVR (pre-discharge, T1), 30-day follow-up (window 3-9 weeks, T2), and 6-month follow-up (T3). Cardiac 4D CT will be performed at the 30-day follow-up visit to screen for the occurrence of HALT.
Patients with HALT will be treated with systemic anticoagulation for 5-6 months, at which point a follow-up CT scan and blood sample will be obtained. Control subjects will also undergo a 6-month study visit with blood sample collection. The study will be conducted within two phases. Phase 1 will serve as a derivation / discovery study in which candidate protein biomarkers of HALT will be identified.
Once this is successfully completed, a second cohort will be enrolled within phase 2. Phase 2 will be performed under the auspices a future contract or amendment and will seek to cross-validate the initial study findings.
The 2 groups in the trial
- HALT CohortOther group
Patients who develop HALT
Treatment: Proteomics Analysis
- Control GroupOther group
Patients who do not develop HALT
Treatment: Proteomics Analysis
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Circulating Biomarkers of Hypo-Attenuated Leaflet Thickening After Transcatheter Aortic Valve Replacement
- Plain-language title
- Blood Proteins as Signs of Valve Leaflet Thickening After Aortic Valve ReplacementGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 10 November 2021